Geneos Wealth Management Inc. Has $391,000 Stock Position in The Clorox Company $CLX

Geneos Wealth Management Inc. grew its position in shares of The Clorox Company (NYSE:CLX) by 70.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,652 shares of the company’s stock after acquiring an additional 1,094 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Clorox were worth $391,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of CLX. Wood Tarver Financial Group LLC bought a new stake in shares of Clorox during the 4th quarter worth approximately $31,000. Ransom Advisory Ltd bought a new stake in shares of Clorox during the 1st quarter worth approximately $35,000. GW&K Investment Management LLC raised its stake in shares of Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock worth $43,000 after purchasing an additional 208 shares in the last quarter. Roble Belko & Company Inc raised its stake in shares of Clorox by 140.7% during the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock worth $53,000 after purchasing an additional 211 shares in the last quarter. Finally, IMA Advisory Services Inc. bought a new stake in shares of Clorox during the 1st quarter worth approximately $58,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Stock Performance

NYSE:CLX opened at $123.75 on Monday. The stock’s 50-day simple moving average is $124.27 and its 200 day simple moving average is $132.14. The firm has a market capitalization of $15.14 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 0.99 and a beta of 0.52. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The Clorox Company has a twelve month low of $116.53 and a twelve month high of $171.37.

Clorox (NYSE:CLX) last released its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.63. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.Clorox’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Wednesday, August 13th were given a $1.24 dividend. This is a boost from Clorox’s previous quarterly dividend of $1.22. This represents a $4.96 annualized dividend and a yield of 4.0%. The ex-dividend date was Wednesday, August 13th. Clorox’s dividend payout ratio is 76.07%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group dropped their price target on Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. UBS Group decreased their price objective on Clorox from $150.00 to $134.00 and set a “neutral” rating on the stock in a report on Thursday, July 17th. Barclays decreased their price objective on Clorox from $129.00 to $119.00 and set an “underweight” rating on the stock in a report on Tuesday, July 15th. Wells Fargo & Company reduced their target price on Clorox from $138.00 to $130.00 and set an “equal weight” rating on the stock in a report on Friday, September 5th. Finally, Citigroup reissued a “neutral” rating and set a $135.00 target price (down from $140.00) on shares of Clorox in a report on Tuesday, July 15th. One investment analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $142.18.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the completion of the transaction, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.57% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.